Robert LeBoyer
Stock Analyst at Noble Capital Markets
(2.15)
# 1,564
Out of 4,413 analysts
14
Total ratings
28.57%
Success rate
3.86%
Average return
Main Sectors:
Top Industries:
13 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| UNCY Unicycive Therapeutics | Initiates: Outperform | $6 | $1.14 | +428.63% | 1 | Feb 14, 2024 | |
| CVKD Cadrenal Therapeutics | Initiates: Outperform | $4 | $0.45 | +780.09% | 1 | Dec 18, 2023 | |
| ELDN Eledon Pharmaceuticals | Initiates: Outperform | $10 | $2.29 | +336.68% | 1 | Sep 27, 2023 | |
| GOVX GeoVax Labs | Initiates: Outperform | $90 | $1.45 | +6,106.90% | 1 | May 8, 2023 | |
| MAIA MAIA Biotechnology | Initiates: Outperform | $14 | $2.92 | +379.45% | 1 | Feb 21, 2023 | |
| TNXP Tonix Pharmaceuticals Holding | Initiates: Outperform | $120 | $0.18 | +67,696.61% | 1 | Apr 18, 2022 | |
| LCTX Lineage Cell Therapeutics | Initiates: Outperform | $8 | $1.13 | +607.96% | 1 | Aug 19, 2021 | |
| PSTV Plus Therapeutics | Initiates: Buy | n/a | $1.72 | - | 1 | Jan 25, 2021 | |
| BNTC Benitec Biopharma | Downgrades: Neutral | n/a | $7.90 | - | 1 | Oct 5, 2020 | |
| AVXL Anavex Life Sciences | Initiates: Buy | n/a | $3.69 | - | 1 | Sep 28, 2020 | |
| CNSP CNS Pharmaceuticals | Initiates: Buy | n/a | $0.22 | - | 1 | Aug 24, 2020 | |
| VTVT vTv Therapeutics | Downgrades: Neutral | n/a | $27.96 | - | 1 | Apr 10, 2018 | |
| NTRP NextTrip | Initiates: Buy | n/a | $2.46 | - | 2 | Mar 8, 2018 |
Unicycive Therapeutics
Feb 14, 2024
Initiates: Outperform
Price Target: $6
Current: $1.14
Upside: +428.63%
Cadrenal Therapeutics
Dec 18, 2023
Initiates: Outperform
Price Target: $4
Current: $0.45
Upside: +780.09%
Eledon Pharmaceuticals
Sep 27, 2023
Initiates: Outperform
Price Target: $10
Current: $2.29
Upside: +336.68%
GeoVax Labs
May 8, 2023
Initiates: Outperform
Price Target: $90
Current: $1.45
Upside: +6,106.90%
MAIA Biotechnology
Feb 21, 2023
Initiates: Outperform
Price Target: $14
Current: $2.92
Upside: +379.45%
Tonix Pharmaceuticals Holding
Apr 18, 2022
Initiates: Outperform
Price Target: $120
Current: $0.18
Upside: +67,696.61%
Lineage Cell Therapeutics
Aug 19, 2021
Initiates: Outperform
Price Target: $8
Current: $1.13
Upside: +607.96%
Plus Therapeutics
Jan 25, 2021
Initiates: Buy
Price Target: n/a
Current: $1.72
Upside: -
Benitec Biopharma
Oct 5, 2020
Downgrades: Neutral
Price Target: n/a
Current: $7.90
Upside: -
Anavex Life Sciences
Sep 28, 2020
Initiates: Buy
Price Target: n/a
Current: $3.69
Upside: -
CNS Pharmaceuticals
Aug 24, 2020
Initiates: Buy
Price Target: n/a
Current: $0.22
Upside: -
vTv Therapeutics
Apr 10, 2018
Downgrades: Neutral
Price Target: n/a
Current: $27.96
Upside: -
NextTrip
Mar 8, 2018
Initiates: Buy
Price Target: n/a
Current: $2.46
Upside: -